Refine by
Lung Condition Articles & Analysis
27 news found
Mold: Common in damp or poorly ventilated areas, mold releases airborne spores that can irritate the lungs and exacerbate chronic respiratory conditions. Fixing leaks, improving airflow, and using dehumidifiers are effective prevention methods. ...
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This ...
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative ...
Founded in 1963, in Maids Moreton, Vitalograph’s mission has remained unwavering over the past six decades – to improve the lives of people living with lung conditions through the development and manufacture of respiratory diagnostic solutions. ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...
Come and meet us (Medha Namjoshi & BMEC.asia team) to know more about this breakthrough technology in airway clearance for patients suffering from chronic lung conditions who need mucus mobilization! ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, such as bronchiectasis, cystic fibrosis, COPD, primary ciliary dyskinesia, severe asthma, etc. ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
” With FRI images, the patient would likely better comprehend the condition of their lungs and how their respiratory functioning improves over the course of the prescribed treatment. ...
ByFluidda
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. ...
“We have more insight into the lung vasculature, tissue, and airways,” De Backer comments. Exemplifying this increased insight, he adds, “We could immediately see what happens in patients with COVID. ...
ByFluidda
“Hantavirus infections and the resulting diseases, Hantavirus Pulmonary Syndrome and Hemorrhagic Fever with Renal Syndrome, are potentially life-threatening conditions with no specific treatment to date,” said Prof. Dr. Oliver Planz, CSO of Atriva Therapeutics. ...
” Whether pinpointing veins for IVs, evaluating cardiological conditions or scanning the lungs of COVID-19 patients, Exo’s powerful device will aim to see deeper and provide more accurate imaging for a wide range of body types, including obese and overweight patients that are hard to scan effectively with current handheld ultrasound technology. ...
ByExo
” Researchers noted that these patients experienced quicker extubation, less lung trauma and less oxygen toxicity. Stemedica went on to receive U.S. ...
VIDA Insights’ comprehensive suite of AI-powered, lung intelligence solutions aid in the management of all major lung diseases, including asthma, emphysema, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and COVID-19. ...
The program is intended to launch in three categories: Population health screening and predictive analytics for conditions such as coronary arterial disease, stroke prevention and osteoporosis; Post-acute triage for urgent conditions such as pneumothorax, acute fractures and pneumonia (including COVID-19); and Routine peer review and quality assurance cases ...